Skip to main content

Table 1 Baseline subject demographics

From: Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study

Variable

 

Group

Active

Placebo

N

 

6

6

Age

Mean (SD)

41 (15)

52 (15)

Sex

#(%) Male

4 (67%)

3 (50%)

Duration UC

Mean (SD) yrs

8.9 (9.1)

9.8 (10.6)

BMI*

Mean (SD)

24 (3)

29 (4)

Treatment with biologic

#(%) yes

2 (33%)

1 (17%)

Fecal calprotectin

Mean (SD)

573 (659)

408 (277)

Total Mayo score

Mean (SD)

6.3 (2.0)

6.7 (1.2)

 Mayo symptom subscore

Mean (SD)

4.8 (1.5)

4.3 (1.0)

 Mayo endoscopic subscore

Mean (SD)

1.5 (0.8)

2.3 (0.5)

Endoscopic UCEIS^ score

Mean (SD)

7.0 (1.8)

8.5 (1.8)

Histologic Severity Score**

Mean (SD)

3.4 (1.2)

4.3 (2.0)

IBDQ^^ total score

Mean (SD)

142.8 (16.8)

120.2 (25.1)

 IBDQ bowel system subscore

Mean (SD)

4.2 (0.7)

4.3 (0.9)

  1. Baseline clinical characteristics of subjects randomized to both the active FMT and placebo study arms
  2. *Body Mass Index
  3. **Geboes Score
  4. ^Ulcerative Colitis Endoscopic Index of Severity
  5. ^^Inflammatory Bowel Questionnaire